Abstract:Aldose reductase (AR) is an aldo-keto reductase that catalyzes the first step in the polyol pathway which converts glucose to sorbitol. Under normal glucose homeostasis the pathway represents a minor route of glucose metabolism that operates in parallel with glycolysis. However, during hyperglycemia the flux of glucose via the polyol pathway increases significantly, leading to excessive formation of sorbitol. The polyol pathway-driven accumulation of osmotically active sorbitol has been implicated in the development of secondary diabetic complications such as retinopathy, nephropathy, and neuropathy. Based on the notion that inhibition of AR could prevent these complications a range of AR inhibitors have been developed and tested; however, their clinical efficacy has been found to be marginal at best. Moreover, recent work has shown that AR participates in the detoxification of aldehydes that are derived from lipid peroxidation and their glutathione conjugates. Although in some contexts this antioxidant function of AR helps protect against tissue injury and dysfunction, the metabolic transformation of the glutathione conjugates of lipid peroxidation-derived aldehydes could also lead to the generation of reactive metabolites that can stimulate mitogenic or inflammatory signaling events. Thus, inhibition of AR could have both salutary and injurious outcomes. Nevertheless, accumulating evidence suggests that inhibition of AR could modify the effects of cardiovascular disease, asthma, neuropathy, sepsis, and cancer; therefore, additional work is required to selectively target AR inhibitors to specific disease states. Despite past challenges, we opine that a more gainful consideration of therapeutic modulation of AR activity awaits clearer identification of the specific role(s) of the AR enzyme in health and disease.

Research Progress in Aldose Reductase

Recent progress of aldose reductase in non-diabetic disease

Role of Aldose Reductase in Diabetic Complications and Angiocardiopathy

Aldose Reductase: a Novel Target for Cardioprotective Intervention after Myocardial Ischemia

Advance in studies on aldose reductase inhibitors from microbial origin

Physiological and Pathological Roles of Aldose Reductase

The Roles of Aldose Reductase in Diabetic Retinopathy

[Progress in Research of Aldose Reductase Inhibitors in Traditional Medicinal Herbs].

Research Progress in the Relationship Between Aldehyde Dehydrogenase and Human Diseases

Aldose Reductase as a Key Target in the Prevention and Treatment of Diabetic Retinopathy: A Comprehensive Review

Genetic Deficiency of Aldose Reductase Counteracts the Development of Diabetic Nephropathy in C57BL/6 Mice.

Investigating the Inhibitory Potential of Flavonoids against Aldose Reductase: Insights from Molecular Docking, Dynamics Simulations, and gmx_MMPBSA Analysis

Aldose reductase is a potential therapeutic target for neurodegeneration

Aldehyde dehydrogenase 1 family: A potential molecule target for diseases

Aldehyde Dehydrogenase 2 as a Therapeutic Target in Oxidative Stress-Related Diseases: Post-Translational Modifications Deserve More Attention

Association of Aldose Reductase and Its Genetic Polymorphisms with Diabetic Chronic Complications

Discovery of New Selective Human Aldose Reductase Inhibitors Through Virtual Screening Multiple Binding Pocket Conformations.

The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature

Aldehyde Dehydrogenases As Promising Targets for Treating Toxic Alde-hyde-related Diseases.

Aldose reductase / polyol inhibitors for diabetic retinopathy.

Aldo–Keto Reductase AKR1C1–AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy